Pharmafile Logo

MK-3102

- PMLiVE

AZ/Merck & Co’s PARP inhibitor Lynparza scores trial win in early breast cancer

Trial halted early after crossing superiority boundary for the primary endpoint of invasive disease-free survival

- PMLiVE

New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer

Data presented at the virtual American Society of Clinical Oncology’s Genitourinary Cancers Symposium

- PMLiVE

Merck’s CEO Kenneth Frazier to retire after ten years in the role

Frazier is handing the reins over to current Merck CFO Robert Davis

- PMLiVE

Merck ends its COVID-19 vaccine programme after disappointing early trial results

Immune responses were inferior to levels observed in recovered COVID-19 patients

- PMLiVE

Merck’s appeal to restore hepatitis C patent verdict against Gilead fails

US Supreme Court rejects Merck’s appeal over patent dispute verdict of $2.54bn

- PMLiVE

Merck submits 15-valent pneumococcal vaccine candidate to EMA and FDA

If approved, this vaccine will closely challenge Pfizer's Prevnar-13

- PMLiVE

Merck strengthens oncology pipeline with $2.75bn VelosBio deal

The deal will give Merck control of VLS-101, an antibody-drug conjugate

OLED Medical Technology Saving Patient’s Sight During COVID-19 Pandemic

North East MedTech company secures investment agreement with Japanese tech giant

Onyx Health

- PMLiVE

TikTok and diabetes awareness

The video-sharing platform TikTok has been fostering huge numbers of people documenting the day-to-day reality of their health conditions. From comedy snippets about diagnosis to personal reviews of health tech,...

11 London

Combating Coronavirus Through Reversing Diabetes

The Diabetes Reversal Company has developed a pioneering programme based on sustainable weight loss, evidence-based lifestyle change and one-to-one clinical support to reduce and reverse the effects of Type 2...

Onyx Health

- PMLiVE

Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links